Induction therapy with adalimumab leads to rapid improvement in the health-related quality of life of patients with moderate to severe Crohn's disease Maintenance therapy with adalimumab results ...

More than 90% of patients with inflammatory bowel disease (IBD) accepted the switch from the adalimumab reference product to adalimumab biosimilars, with favourable survival and remission outcomes ...

The U.S. Food and Drug Administration (FDA) has granted an expanded interchangeable designation for Celltrion’s YUFLYMA.

#Data provided for the iv. administration only. ADM: Adalimumab; AUC 0-∞: Area under the plasma concentration-time curve from time zero to infinity; CL/F: Apparent total clearance of the drug ...

The patient was receiving mesalazine and 6-mercaptopurine and, 2 months before admission, had stopped a 4-month therapy course with the biologic agent adalimumab for treatment of Crohn's disease.